Bladder Cancer

Comparison of quality of urinary bladder filling in CT urography with different doses of furosemide in the work-up of patients with macroscopic hematuria.

The protocol for preparation of computed tomography urography (CTU) examinations at our hospital was changed in 2013 to improve the quality of urinary bladder filling in the excretory phase. The aim of this study was to evaluate the quality of urinary bladder filling on CTU after different doses of furosemide were administered to patients with macroscopic hematuria.

Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor.

The present research was performed to clarify the differences in circulating tumor cells (CTCs) counts between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer following transurethral resection of bladder tumor (TURBT).

Neoadjuvant chemotherapy before radical cystectomy: why we must adhere?

To provide a critical literature review on state of the art and novel strategies in the field of neoadjuvant treatments for muscle-invasive bladder cancer (MIBC).

a nonsystematic literature review was performed using PubMed, Scopus and Clinical Trials.

Comparison of the performance of ADXBLADDER test and urinary Cytology in the follow up of Non-Muscle Invasive Bladder Cancer: a blinded prospective multicentric study.

The objective of the study was to directly compare the performance of ADXBLADDER and cytology in the detection of NMIBC recurrences.

ADXBLADDER is a urine test based upon the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing.

Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis.

Cancer-related changes in sexual function (SF) negatively impact quality of life and intimate partner relationships. There is a lack of data regarding SF among patients who underwent radical cystectomy (RC).

Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.

To investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who underwent adjuvant induction bacillus Calmette-Guérin (BCG) therapy after transurethral resection of bladder tumor (TURBT).

Partitioning of time trends in prevalence and mortality of bladder cancer in the United States.

The aim of the study was to evaluate the relative contributions of incidence, stage-specific relative survival, and stage ascertainment to changes in bladder cancer (BC) prevalence and incidence-based mortality.

Bioinformatic identification of prognostic indicators in bladder cancer.

Aim: Bladder cancer (BC) is one of the most common malignancies with poor prognosis. We aimed to identify a genetic signature for predicting the prognosis of BC. Materials & methods: Kaplan-Meier survival and Cox regression analyses were used to construct a prognostic signature using data from The Cancer Genome Atlas.

Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.

Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5-15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer.

Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?

The purpose of this study was to evaluate the effect of neoadjuvant chemotherapy (NACT) on squamous variant (SV) bladder cancer by investigating patients presenting with SV histology at the time of transurethral resection (TUR), stratified by their receipt of NACT.

Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.

There is a need for effective nonsurgical treatment options in patients with nonmuscle invasive bladder cancer (NMIBC) in whom Bacillus Calmette-Guerin (BCG) therapy has failed.

We aimed to determine the efficacy of Electromotive Drug Administration (EMDA) of mitomycin C (MMC) with NMIBC after BCG failure.

Quantification and correction of distortion in diffusion-weighted-MRI at 1.5 and 3 T in a muscle-invasive bladder cancer phantom for radiotherapy planning.

Limited visibility of post-resection muscle-invasive bladder cancer (MIBC) on CT hinders radiotherapy dose escalation of the residual tumour. Diffusion-weighted magnetic resonance imaging (DW-MRI) visualizes areas of high tumour burden and is increasingly used within diagnosis and as a biomarker for cancer.

SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia.

In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status; therefore, data on cancer patients must be available in order to consider the most adequate strategy of care.

Gender Disparities in Bladder Cancer Specific Survival in High Poverty Areas Utilizing Ohio Cancer Incidence Surveillance System (OCISS).

To better understand the interplay of socioeconomic and demographic traits on bladder cancer outcomes utilizing the Ohio state cancer registry, Ohio Cancer Incidence Surveillance System (OCISS).

We obtained demographic, clinical and outcome data on 47,182 bladder cancer cases diagnosed from 1996-2016 from OCISS.

Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non–muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland’s Quality Performance Indicators Programme

Background: Clinical outcomes from non–muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC).

Objective: To evaluate compliance with specific quality indicators (QIs) related to transurethral resection of bladder tumour (TURBT) and to understand clinical outcomes from NMIBC following the introduction of the QPI programme.

Design, setting, and participants: Within a robust governance framework, 12 mandatory evidence-based QPIs were implemented nationally in April 2014. We report prospectively collected data for all new BC patients (between April 2014 and March 2017). We include follow-up data for 2689 (63%) patients.

Intervention: The TURBT-related QPIs were (1) using a bladder diagram, (2) single post-TURBT instillation of mitomycin C (SPI-MMC), (3) detrusor muscle (DM) in the specimen, and (4) early re-TURBT in high-risk NMIBC.

Outcome measurements and statistical analysis: We measured compliance with these QPIs and (1) recurrence rate at first follow-up cystoscopy (RRFFC), (2) rates of residual cancer, and (3) pT2 cancer at re-TURBT. Associations between QPI compliance, tumour features, and outcomes were assessed with multivariable logistic regression models.

Results and limitations: Among 4246 new BC patients, SPI-MMC was used in 67% (2029/3023) NMIBC patients. In 1860 NMIBC patients undergoing TURBT, RRFFC, rate of residual cancer, and rate of pT2 at re-TURBT were 13% (116/888), 33% (212/653), and 2.9% (19/653), respectively. SPI-MMC was associated with lower RRFFC, independent of all variables including hospital volume and surgeon. Presence of DM in the specimen halved the likelihood of residual disease in pT1 cancers. The main limitation is the lack of a pre-QPI introduction cohort for comparison.

Conclusions: The implementation of a QI programme in Scotland appears to facilitate high-quality TURBT, which in a real-world setting is associated with low early recurrence/residual cancer and accurate pathological staging.

Patient summary: Following the first 3 yr of implementing a novel Quality Performance Indicator (QPI) programme in Scotland, we assessed compliance and outcomes in non–muscle-invasive bladder cancer. Evaluating over 4000 new bladder cancer patients, we found that the QPI programme was associated with low recurrence and accurate staging following the initial transurethral resection of bladder tumour.

Authors: Paramananthan Mariappan, Allan Johnston, Luisa Padovani, Eilidh Clark, Matthew Trail, Sami Hamid, Graham Hollins, Helen Simpson, Benjamin G. Thomas, Rami Hasan, Jaimin Bhatt, Imran Ahmad, Ghulam M. Nandwani. Ian D.C. Mitchell, David Hendry, for members of the Scottish Bladder Cancer QPI Research Collaborative

Author Affiliations: Department of Urology, Western General Hospital, University of Edinburgh, Crewe Road South, Edinburgh; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK; University of Edinburgh, Edinburgh, UK; Department of Urology, Ninewells Hospital, Dundee, UK; Department of Urology, Ninewells Hospital, Dundee, UK; Department of Urology, Victoria Hospital, Kirkcaldy, UK; Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh, UK, Department of Urology, Borders General Hospital, Melrose, UK; Department of Urology, University Hospital Ayr, Ayr, UK; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK; Department of Urology, Ninewells Hospital, Dundee, UK; Department of Urology, Victoria Hospital, Kirkcaldy, UK; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK

Source: Mariappan P, Johnston A, Padovani L, et al. "Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme." Eur Urol. July 17 2020. doi: https://doi.org/10.1016/j.eururo.2020.06.051

Clinicopathological Characteristics and Survival Outcomes in Micropapillary Urothelial Carcinoma of the Bladder — Expert Commentary

Micropapillary urothelial carcinoma (MPUC) is a rare and aggressive histological variant of urinary bladder cancer. A recent study published by Jin et al. in Cancer Medicine investigated the prognosis and survival rates of MPUC compared to conventional urothelial cancer (UC).

Bladder cancer in Ireland: a 21-year review.

Bladder carcinoma is one of the most commonly diagnosed cancers worldwide; however, various studies have reported on marked international variation in incidence and mortality rates. The aim of this study was to report national figures on incidence, survival and risk factors of bladder cancer.

Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomy?

Imaging characteristics in bladder cancer (BC), such as hydronephrosis, are predictive of ≥ pT3 disease at time of radical cystectomy (RC). The predictive capacity of other findings, such as perivesical stranding (PS), remains unclear.

Urinary exfoliated tumor single-cell metabolomics technology for establishing a drug resistance monitoring system for bladder cancer with intravesical chemotherapy.

Bladder cancer is one of the most common urogenital malignant with a rising incidence rate all over the world. Non-muscle invasive bladder cancer (NMIBC) has the characteristics of high recurrence rate and easy progression after receiving transurethral tumor resection combined with intravesical chemotherapy.

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

The impact of sex hormones on cancer immunotherapy remains controversial. Androgens, via the androgen receptor (AR), may impact the success of immune checkpoint blockade. This study characterizes AR and programmed death ligand-1 (PD-L1) expression in bladder tumors with long clinical follow-up.